Clinical trials: Enthesitis Related Arthritis
Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.
- Trial name
- NCT06668181
- Testing
- Bimekizumab
- Where
- 23 sites in Canada, France and 4 more
- Volunteers
- 40 people
- Sponsor
- UCB Biopharma SRL
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing…
- Trial name
- NCT04527380
- Testing
- Ixekizumab, Adalimumab
- Where
- 43 sites in Argentina, Belgium and 10 more
- Volunteers
- 101 people
- Sponsor
- Eli Lilly and Company
Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related…
- Trial name
- NCT03769168
- Testing
- Secukinumab
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Enthesitis-related Arthritis (ERA), Juvenile Psoriatic Arthritis (JPsA)
Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.
The goal of this study is to understand the long-term treatment strategies in children and adolescents diagnosed with ERA or JPsA who received secukinumab and achieved inactive disease and to evaluate the long-term treatment…
- Trial name
- NCT07190053
- Testing
- Secukinumab
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
This was a double-blind, placebo-controlled, event-driven randomized withdrawal study to investigate the efficacy and safety of secukinumab treatment in the Juvenile Idiopathic Arthritis (JIA) categories of Juvenile Psoriatic…
- Trial name
- NCT03031782
- Testing
- secukinumab
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Enthesitis Related Arthritis (ERA)
A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
The purpose of this study is to evaluate the efficacy and safety of adalimumab given subcutaneously every other week (eow) as compared to placebo in pediatric subjects with Enthesitis Related Arthritis (ERA).
- Trial name
- NCT01166282
- Testing
- adalimumab
- Volunteers
- 46 people
- Sponsor
- AbbVie (prior sponsor, Abbott)